Your browser is no longer supported. Please, upgrade your browser.
Settings
ZYME [NYSE]
Zymeworks Inc.
Index- P/E- EPS (ttm)-4.35 Insider Own0.70% Shs Outstand51.42M Perf Week5.49%
Market Cap1.29B Forward P/E- EPS next Y-3.35 Insider Trans-14.18% Shs Float41.69M Perf Month-28.14%
Income-222.60M PEG- EPS next Q-1.14 Inst Own76.70% Short Float8.79% Perf Quarter-28.12%
Sales20.70M P/S62.46 EPS this Y6.30% Inst Trans0.05% Short Ratio7.60 Perf Half Y-5.64%
Book/sh6.25 P/B4.15 EPS next Y0.20% ROA-43.00% Target Price- Perf Year-42.39%
Cash/sh7.22 P/C3.59 EPS next 5Y11.00% ROE-57.80% 52W Range24.41 - 59.03 Perf YTD-45.11%
Dividend- P/FCF- EPS past 5Y-16.10% ROI-45.80% 52W High-56.06% Beta1.01
Dividend %- Quick Ratio4.70 Sales past 5Y32.20% Gross Margin- 52W Low6.27% ATR1.77
Employees425 Current Ratio4.70 Sales Q/Q-85.50% Oper. Margin- RSI (14)38.56 Volatility5.04% 6.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.20% Profit Margin- Rel Volume1.45 Prev Close24.74
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume481.86K Price25.94
Recom1.80 SMA20-9.16% SMA50-16.56% SMA200-25.54% Volume700,936 Change4.85%
Oct-07-21Initiated Jefferies Hold $32
Mar-31-21Initiated Credit Suisse Outperform $55
Feb-25-21Downgrade SVB Leerink Outperform → Mkt Perform $41
Feb-08-21Resumed H.C. Wainwright Buy $57
Jan-25-21Downgrade Citigroup Buy → Neutral $50 → $53
Sep-29-20Resumed JP Morgan Neutral $48
Aug-06-20Initiated SVB Leerink Outperform $45
Jan-10-20Initiated Wolfe Research Outperform $61
Dec-09-19Initiated JP Morgan Neutral
Nov-25-19Initiated H.C. Wainwright Buy $65
Nov-20-19Initiated Guggenheim Buy
Sep-30-19Upgrade Raymond James Outperform → Strong Buy $36 → $40
Aug-30-19Initiated Stifel Buy $45
Jul-18-19Initiated Deutsche Bank Buy $34
May-11-18Upgrade Barclays Underweight → Equal Weight $8 → $15
Mar-19-18Initiated Raymond James Outperform
Oct-11-21 10:00AM  
Sep-17-21 01:52PM  
Sep-16-21 11:43AM  
05:30AM  
Sep-12-21 06:49PM  
Sep-03-21 12:23PM  
Aug-10-21 09:38AM  
Aug-04-21 07:45PM  
04:15PM  
Aug-03-21 08:30AM  
Jul-28-21 03:03PM  
08:30AM  
Jul-19-21 02:27PM  
Jul-13-21 09:22AM  
Jul-08-21 08:30AM  
May-26-21 08:30AM  
May-06-21 08:30AM  
May-05-21 08:55PM  
04:15PM  
Apr-29-21 05:02PM  
Apr-22-21 05:15PM  
Apr-20-21 08:45AM  
Apr-19-21 08:30AM  
Apr-13-21 08:30AM  
Apr-10-21 08:30AM  
Mar-22-21 06:55AM  
Mar-10-21 05:27PM  
Feb-24-21 04:15PM  
Feb-12-21 07:30AM  
Feb-10-21 04:15PM  
Feb-09-21 04:30PM  
Jan-28-21 04:24PM  
11:44AM  
08:03AM  
Jan-27-21 05:15PM  
Jan-25-21 07:54PM  
Jan-15-21 08:30AM  
Jan-11-21 08:00AM  
Jan-07-21 08:30AM  
Jan-05-21 08:52AM  
Dec-19-20 02:44PM  
Dec-10-20 08:30AM  
Dec-02-20 08:00AM  
Dec-01-20 08:30AM  
Nov-30-20 08:30AM  
Nov-19-20 08:30AM  
Nov-17-20 08:31AM  
Nov-16-20 04:15PM  
Nov-10-20 08:30AM  
Nov-03-20 04:15PM  
Sep-20-20 07:32AM  
Sep-15-20 12:49AM  
Sep-03-20 08:30AM  
Aug-06-20 08:43AM  
Aug-05-20 08:55PM  
04:15PM  
Jul-31-20 12:30PM  
Jul-12-20 01:17PM  
Jul-08-20 05:30PM  
04:15PM  
Jun-30-20 08:30AM  
Jun-24-20 08:41AM  
Jun-11-20 09:03AM  
Jun-08-20 04:13PM  
May-28-20 08:30AM  
May-08-20 08:30AM  
May-07-20 08:50PM  
04:15PM  
Apr-30-20 12:34PM  
Apr-15-20 02:50PM  
Apr-01-20 04:15PM  
Mar-16-20 06:50AM  
Mar-02-20 05:45PM  
04:15PM  
Feb-26-20 12:30PM  
Feb-24-20 08:30AM  
Jan-27-20 09:45AM  
Jan-22-20 09:46PM  
Jan-21-20 04:08PM  
Jan-13-20 08:30AM  
Jan-12-20 10:00AM  
Jan-07-20 08:30AM  
Dec-11-19 01:58PM  
Dec-05-19 01:35PM  
Nov-22-19 08:18AM  
02:30AM  
Nov-18-19 08:30AM  
Nov-05-19 06:45PM  
06:00PM  
04:15PM  
Nov-04-19 04:15PM  
Oct-29-19 10:32AM  
Oct-28-19 12:37PM  
08:30AM  
Oct-16-19 04:15PM  
Oct-01-19 02:14PM  
Sep-28-19 08:30AM  
Sep-17-19 06:45AM  
Aug-28-19 05:00PM  
Aug-26-19 07:42AM  
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Polverino Anthony J.Chief Scientific OfficerAug 31Option Exercise15.004,90073,50036,333Sep 02 08:00 PM
Tehrani AliChief Executive OfficerJul 16Option Exercise4.2641,191175,651301,516Jul 16 09:30 PM
Tehrani AliChief Executive OfficerJul 16Sale36.0041,1911,482,876260,325Jul 16 09:30 PM
Tehrani AliChief Executive OfficerJul 15Option Exercise4.273,80016,231264,125Jul 16 09:30 PM
Tehrani AliChief Executive OfficerJul 15Sale36.003,800136,800260,325Jul 16 09:30 PM
Tehrani AliChief Executive OfficerJul 12Option Exercise4.3112,66954,555272,994Jul 13 08:00 PM
Tehrani AliChief Executive OfficerJul 12Sale36.1212,669457,635260,325Jul 13 08:00 PM
Priour JamesChief Commercial OfficerApr 13Option Exercise0.002,26602,953Apr 13 09:30 PM
Priour JamesChief Commercial OfficerApr 13Sale27.9395026,5332,003Apr 13 09:30 PM
O'Driscoll KathrynChief People OfficerMar 15Option Exercise34.2483728,6595,840Mar 17 08:00 PM
O'Driscoll KathrynChief People OfficerMar 15Sale34.7278627,2905,003Mar 17 08:00 PM
HAUSMAN DIANAChief Medical OfficerMar 10Option Exercise0.002,50006,425Mar 12 08:00 PM
Klompas Neil AChief Financial OfficerMar 10Option Exercise0.002,500011,896Mar 12 08:00 PM
O'Driscoll KathrynChief People OfficerMar 10Option Exercise0.001,35406,357Mar 12 08:00 PM
Polverino Anthony J.Chief Scientific OfficerMar 10Option Exercise0.002,500032,027Mar 12 08:00 PM
Tehrani AliChief Executive OfficerMar 10Option Exercise0.007,7080264,717Mar 12 08:00 PM
Polverino Anthony J.Chief Scientific OfficerMar 10Sale34.951,04836,63130,979Mar 12 08:00 PM
O'Driscoll KathrynChief People OfficerMar 10Sale34.9556819,8545,789Mar 12 08:00 PM
Tehrani AliChief Executive OfficerMar 10Sale34.954,392153,516260,325Mar 12 08:00 PM
Klompas Neil AChief Financial OfficerMar 10Sale34.951,42549,80910,471Mar 12 08:00 PM
HAUSMAN DIANAChief Medical OfficerMar 10Sale34.951,04836,6315,377Mar 12 08:00 PM
O'Driscoll KathrynChief People OfficerFeb 12Option Exercise34.242,08371,3225,003Feb 16 08:21 PM
Klompas Neil AChief Financial OfficerDec 09Option Exercise5.1825,000129,39934,122Dec 11 07:30 PM
Klompas Neil AChief Financial OfficerDec 09Sale53.2525,0001,331,1329,122Dec 11 07:30 PM
Tehrani AliChief Executive OfficerDec 07Sale56.1685047,73655,511Dec 09 07:35 PM
HAUSMAN DIANAChief Medical OfficerDec 04Option Exercise10.896,03265,6629,750Dec 04 07:45 PM
HAUSMAN DIANAChief Medical OfficerDec 04Sale55.126,032332,4763,718Dec 04 07:45 PM
HAUSMAN DIANAChief Medical OfficerDec 02Option Exercise11.477018,0434,419Dec 03 07:54 PM
HAUSMAN DIANAChief Medical OfficerDec 02Sale55.0170138,5633,718Dec 03 07:54 PM
HAUSMAN DIANAChief Medical OfficerDec 01Option Exercise11.3818,267207,95521,985Dec 03 07:54 PM
HAUSMAN DIANAChief Medical OfficerDec 01Sale55.1918,2671,008,2403,718Dec 03 07:54 PM
O'Driscoll KathrynChief People OfficerNov 18Option Exercise34.242,92099,9812,920Nov 19 08:00 PM
Tehrani AliChief Executive OfficerNov 02Sale39.043,500136,62456,361Nov 04 09:37 PM